

commonly used for single sex, single species carcinogens such as bromoxynil that are thought to work through secondary mechanisms. Nevertheless, the risk assessments filed with this petition have been performed using quantitative risk assessment methodology. Accordingly, the upper-bound risk estimate for the general U.S. population represented by all sources of bromoxynil exposure, including use of bromoxynil on up to 10% of the U.S. treated acreage is approximately 2×10^{-6} .

2. *Infants and children.* To estimate acute dietary risk for systemic effects other than developmental from food sources, an MOE of 270 was calculated using 1-day dietary exposure for infants (the most highly exposed population group) and a NOEL of 8 mg/kg/day derived from a 13-week oral toxicity study in dogs. It is concluded that reliable data support use of the standard hundredfold margin of exposure/safety factor in assessing the risk to children. The general U.S. population and all population sub-groups are estimated to be exposed at a level less than 1 percent of the bromoxynil RfD of 0.015 mg/kg/day. Both chronic and acute assessments show no appreciable threshold risks to children and the non-threshold cancer risk is no greater than negligible. Therefore, there is a reasonable certainty that no harm will result to infants and children from aggregate exposure to bromoxynil.

Two multi-generation rodent reproduction studies demonstrated that there were no adverse effects on reproductive performance, fertility, fecundity, pup survival, or pup development. Maternal and developmental NOELs and LOELs were comparable indicating no increase susceptibility of developing organisms. No evidence of endocrine effects were noted in any study. It is therefore concluded that bromoxynil poses no additional risk for infants and children and no additional uncertainty factor is warranted.

F. International Tolerances

There are no Codex tolerances established for bromoxynil residues, therefore international compatibility is not considered to be an issue at this time.

[FR Doc. 97-30812 Filed 11-25-97; 8:45 am]

BILLING CODE 6560-50-F

ENVIRONMENTAL PROTECTION AGENCY

[FRL-5927-7]

Proposed Settlement Pursuant to Section 122(g) of the Comprehensive Environmental Response, Compensation, and Liability Act, Regarding the Sealand Restoration Superfund Site, Lisbon, New York

AGENCY: Environmental Protection Agency.

ACTION: Notice of proposed administrative settlement and opportunity for public comment.

SUMMARY: In accordance with section 122(i) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA), 42 U.S.C. 9622(i), the U.S. Environmental Protection Agency (EPA), Region II, announces a proposed administrative *de minimis* settlement pursuant to section 122(g)(4) of CERCLA, 42 U.S.C. 9622(g)(4), relating to the Sealand Restoration Superfund Site (Site). The Site is located on Pray Road in the Town of Lisbon, St. Lawrence County, New York. This document is being published pursuant to section 122(i) of CERCLA to inform the public of the proposed settlement and give it the opportunity to comment. EPA will consider any comments received during the comment period and may withdraw or withhold consent to the proposed settlement if comments disclose facts or considerations which indicate that the proposed settlement is inappropriate, improper, or inadequate.

The proposed *de minimis* settlement between EPA and Westpoint Stevens Inc., on behalf of former Cluett, Peabody & Co. (Respondent) has been memorialized in an Administrative Order on Consent (Index Number CERCLA-97-0215). This Order will become effective after the close of the public comment period, unless comments received disclose facts or considerations which indicate the Agreement is inappropriate, improper, or inadequate, and EPA, in accordance with section 122(i)(3) of CERCLA, modifies or withdraws its consent to the Agreement. Under the Order, the Respondent will be obligated to make payments to the Hazardous Substance Superfund in reimbursement of EPA's response costs relating to the Site, plus a premium, based on documented volumes of substances in EPA's records associated with the Site, totaling \$47,676.

Pursuant to CERCLA section 122(h)(1), the Order may not be issued

without the prior written approval of the Attorney General or her designee. In accordance with that requirement, the Attorney General or her designee has approved the proposed administrative order in writing.

DATES: Comments must be provided on or before December 26, 1997.

ADDRESSES: Comments should be addressed to the U.S. Environmental Protection Agency, Office of Regional Counsel, New York/Caribbean Superfund Branch, 17th Floor, 290 Broadway, New York, New York 10007-1866, and should refer to: "Sealand Restoration Superfund Site, U.S. EPA Index No. CERCLA-97-0215". For a copy of the settlement document, contact the individual listed below.

FOR FURTHER INFORMATION CONTACT: Elizabeth Davis, Assistant Regional Counsel, New York/Caribbean Superfund Branch, Office of Regional Counsel, U.S. Environmental Protection Agency, 17th Floor, 290 Broadway, New York, New York 10007. Telephone: (212) 637-3165.

Dated: November 4, 1997.

William J. Muszynski,

Acting Regional Administrator.

[FR Doc. 97-31137 Filed 11-25-97; 8:45 am]

BILLING CODE 6560-50-P

COUNCIL ON ENVIRONMENTAL QUALITY

Notice of Meeting; Postponement

SUMMARY: The Council on Environmental Quality (CEQ) is postponing a public meeting it had previously scheduled for December 2, 1997, to discuss development of a memorandum of understanding on coordinating environmental response actions with natural resource restoration under the Comprehensive Environmental Response, Compensation, and Liability Act and other laws. 62 FR 51660 (October 2, 1997). CEQ intends to reschedule the meeting for late January or early February, 1998. CEQ will soon publish another **Federal Register** notice identifying the time, place, and agenda for the meeting.

FOR FURTHER INFORMATION CONTACT: Mary Morton at (202) 208-3302.

Bradley M. Campbell,

Associate Director.

[FR Doc. 97-31031 Filed 11-25-97; 8:45 am]

BILLING CODE 3125-01-M